Becton Dickinson and Company (BDX) 177.88 $BDX BD to

New Post Public Reply Private Reply Replies (0) Message Board

Sep 6, 2016 at 11:11 PM

Becton Dickinson and Company (BDX) 177.88 $BDX

BD to Present at the Morgan Stanley Global Healthcare Conference 2016
PR Newswire - Tue Sep 06, 7:00AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Morgan Stanley Global Healthcare Conference 2016 on Tuesday, September 13, 2016, at 10:35 a.m. EDT.
BDX: 177.88 (+0.56)

BD Submits Pre-Market Approval Application to FDA for BD Onclarity(TM) HPV Test
PR Newswire - Tue Sep 06, 5:59AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has submitted a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the BD Onclarity(TM) HPV Assay, its human papillomavirus (HPV) test.
BDX: 177.88 (+0.56)

Becton, Dickinson Hits 52-Week High on Solid Q3, Outlook
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 10:13AM CDT
Shares of Becton, Dickinson and Company (BDX) scaled a new 52-week high of $178.79 on Jul 31, eventually closing nominally lower at $177.21.
BABY: 42.11 (+1.47), BDX: 177.88 (+0.56), MASI: 59.54 (-0.36), NUVA: 66.44 (-0.30)

Mayo Clinic Proceedings Publishes New Insulin Injection and Infusion Recommendations
PR Newswire Europe - Thu Sep 01, 7:59AM CDT
New Recommendations Based on Findings from Largest-Ever International Survey of more than 13,200 Insulin-Injecting Patients from 42 Countries
BDX: 177.88 (+0.56)

BD Celebrates 60 Years In Sandy, Utah
PR Newswire - Thu Aug 18, 5:59AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined by senior public officials today to celebrate the 60th anniversary of its manufacturing facility in Sandy, Utah. BD also announced that it recently approved a $20 million investment in the BD Sandy site as part of its broader plan to invest in manufacturing capacity and support anticipated growth in the catheter solutions platform.
BDX: 177.88 (+0.56)

BD Cited As Infusion Pump EMR Integration Leader In KLAS Report
PR Newswire - Tue Aug 16, 5:59AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its Alaris(TM) System infusion platform was cited as having the most customers live with bidirectional electronic medical record (EMR) integration, which health care providers said is the most important next step for improving safety to help reduce pump-programming errors in the Smart Pumps 2016: The Quest for Patient Safety report issued by KLAS.
BDX: 177.88 (+0.56)

Medtronic Launches MiniMed 630G, Expands in Diabetic Care (revised)
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 4:34PM CDT
The MiniMed 630G basically combines SmartGuard technology which is already featured in the MiniMed 530G system with a brand new user-friendly design.
ABT: 42.16 (+0.07), BDX: 177.88 (+0.56), DXCM: 94.28 (+2.19), MDT: 87.17 (-0.15)

Medtronic Launches MiniMed 630G, Expands in Diabetic Care
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 9:15AM CDT
Medtronic plc's (MDT) MiniMed 630G system with SmartGuard technology recently won the U.S. FDA approval for its commercial launch.
ABT: 42.16 (+0.07), BDX: 177.88 (+0.56), DXCM: 94.28 (+2.19), MDT: 87.17 (-0.15)

Top 4 Research Reports for August 11, 2016
Sheraz Mian - Zacks Investment Research - Thu Aug 11, 11:40AM CDT
Top 4 Research Reports for August 11, 2016
BDX: 177.88 (+0.56), FOXA: 24.42 (-0.13), PSA: 224.37 (-2.42), SO: 52.13 (+0.33), PCLN: 1,436.96 (+14.11), TWX: 78.39 (-0.14)

Becton Dickinson Falls 3.68% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Aug 04, 11:54AM CDT
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $166.35 to a high of $169.32. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $174.30 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 177.88 (+0.56)

Watch for Becton Dickinson to Potentially Rebound After Falling 3.68% Yesterday
Comtex SmarTrend(R) - Thu Aug 04, 11:52AM CDT
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $166.35 to a high of $169.32. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $174.30 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 177.88 (+0.56)

Becton, Dickinson (BDX) Tops Q3 Earnings, FY16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:02AM CDT
Becton, Dickinson and Company (BDX), reported third-quarter fiscal 2016 earnings of $2.35 per share, which beat the Zacks Consensus Estimate by 16 cents.
HYH: 36.65 (+0.08), BDX: 177.88 (+0.56), ALGN: 95.26 (-0.52), MMSI: 24.44 (-0.05)

Becton, Dickinson (BDX) Beats Q3 Earnings & Revenues
Aniruddha Ganguly - Zacks Investment Research - Thu Aug 04, 6:26AM CDT
Becton, Dickinson???s (BDX) adjusted earnings of $2.35 per share beat the Zacks Consensus Estimate by 16 cents.
BDX: 177.88 (+0.56)

BD Announces Results For 2016 Third Fiscal Quarter
PR Newswire - Thu Aug 04, 5:00AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced quarterly revenues of $3.198 billion, as reported, for the third fiscal quarter ended June 30, 2016, an increase of 2.5 percent over the prior-year period revenues as reported. On a comparable, currency-neutral basis, third quarter organic adjusted revenues grew 4.0 percent.
BDX: 177.88 (+0.56)

Dental Stocks Releasing Earnings on Aug 4: BDX, HSIC, VWR
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:16AM CDT
For the rest of Q2, earnings for Medical companies are expected to rise 3.4%. Dentistry, a niche industry within the broader Medical sector, holds a lot of potential at this moment.
BDX: 177.88 (+0.56), VWR: 26.74 (-1.05), HSIC: 164.31 (+0.02)

Becton Dickinson (BDX) Breaks Through Support at $175.25
Comtex SmarTrend(R) - Mon Aug 01, 8:48AM CDT
Shares of Becton Dickinson (NYSE:BDX) opened today below their pivot of $176.12 and have already reached the first level of support at $175.25. Investors may be interested in a cross of the next downside pivot targets of $174.51 and $172.90.
BDX: 177.88 (+0.56)

Becton Dickinson Has Returned 23.6% Since SmarTrend Recommendation (BDX)
Comtex SmarTrend(R) - Fri Jul 29, 1:57PM CDT
SmarTrend identified an Uptrend for Becton Dickinson (NYSE:BDX) on February 17th, 2016 at $143.14. In approximately 5 months, Becton Dickinson has returned 23.55% as of today's recent price of $176.85.
BDX: 177.88 (+0.56)

Becton, Dickinson (BDX) Q3 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:01AM CDT
Becton, Dickinson and Company (BDX) is set to report third-quarter fiscal 2016 earnings results on Aug 4.
BDX: 177.88 (+0.56), ANIP: 61.55 (+1.69), GLYC: 7.33 (+0.08), NKTR: 18.93 (+0.48)

BD Names R. Andrew Eckert To Board Of Directors
PR Newswire - Thu Jul 28, 3:15PM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that R. Andrew "Andy" Eckert has been appointed to the company's Board of Directors, effective Sept. 26, bringing the total number of directors to 13.
BDX: 177.88 (+0.56), MDSY: 1.30 (-0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Larry Ellison's Moves Signal Confidence in Oracle's Future

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

OneOdio Showcases Innovation at IFA 2026 in Berlin

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

USPS Honors 150 Years of the U.S. Coast Guard Academy

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Protecting Teeth: Insights from Endodontist Dr. Joubert

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Ajman Spotlights Tourism at Arabian Travel Market 2026

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

PureHealth's Acid Reflux Solutions: An Investor's Insight

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...